Source: Zomedia Pharmaceuticals, Inc. 7/17/19
Zomedica Pharmaceuticals Corp.
(NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and
pharmaceutical company, announced it has initiated the development of a
digital customer data platform to enhance customer experience and its
diagnostic pipeline.
Development efforts are focused on
providing veterinarians access to diagnostic test result data and
insights into patterns of disease across animal populations. The
platform is also intended to support veterinary teams with clinically
relevant business services, including inventory management and key
performance metrics reporting. Zomedica believes that the data provided
through the platform will enable it to provide valuable insights from
its entire pipeline of diagnostic testing assays to veterinary care
teams, with the potential to improve the standard of care and patient
outcomes.
The digital platform is being designed to seamlessly
integrate with all of its platforms beginning with TRUFORMA™,
Zomedica’s first to market, point-of-care biosensor platform. Zomedica
believes that the combination of rapid, accurate adrenal (cortisol and
endogenous ACTH) and thyroid (total T4, free T4, and TSH) test result
data with advanced analysis should improve clinical care and hospital
efficiency.
“We believe that the ability to quickly and
thoroughly analyze patient test results with a tool that personalizes
the analysis to your patient will significantly enhance patient care,”
said Dr. Stephanie Morley, Chief Operations Officer and Vice President
of Product Development. “As a clinician, confidence in your diagnosis is
key to assisting the veterinary care team in making treatment
recommendations faster, resulting in more positive outcomes for
patients, and pet owners.”
Zomedica believes that access to
clinically relevant data has the potential to improve the standard of
care, pet owner experience, and patient care. Zomedica intends to seek
potential partnerships within the animal health and technology sectors
to develop integrated solutions to elevate veterinary medicine and
enhance the capabilities of its digital platform.
Zomedica anticipates launching its digital platform in Q1 2020 upon its product launch.
About Zomedica
Based
in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) (TSX-V: ZOM) is a
veterinary diagnostic and pharmaceutical company creating products for
companion animals (canine, feline and equine) by focusing on the unmet
needs of clinical veterinarians. Zomedica’s product portfolio will
include novel diagnostics and innovative therapeutics that emphasize
patient health and practice health. With a team that includes clinical
veterinary professionals, it is Zomedica’s mission to give veterinarians
the opportunity to lower costs, increase productivity, and grow revenue
while better serving the animals in their care. For more information,
visit www.ZOMEDICA.com.
No comments:
Post a Comment